王飞羽 江震 刘亦伟

    摘 要 目的：探讨2型糖尿病(T2DM)患者胰高血糖素样肽-1受体(GLP-1R)基因单核苷酸多态性与利拉鲁肽疗效的关联性。方法：入选的T2DM患者给予利拉鲁肽12周，测定治疗前后糖化血红蛋白(HbA1c)水平。同时对其GLP-1R基因单核苷酸多态性(rs6923761、rs10305420、rs3765467、rs2254336)进行检测，统计分析降糖疗效与基因多态性的相关性。结果：最终纳入的62例患者，与野生型相比，HbA1c值在s3765467纯突变型(AA)患者中下降更显著(P<0.05)，但在其余各基因型患者间无显著差异。结论：rs3765467基因多态性可能影响利拉鲁肽的降糖疗效，未发现rs6923761、rs10305420、rs2254336基因多态性对利拉鲁肽降糖疗效的影响。

    关键词 2型糖尿病 利拉鲁肽 基因多态性 降糖疗效

    中图分类号：R977.15； R587.1 文献标志码：B 文章编号：1006-1533(2021)23-0021-04

    基金項目：福建省中青年教师教育科研项目(JT180186)；福建医科大学启航基金项目(2018QH1071)

    The relationship between GLP-1R gene polymorphism and the efficacy of liraglutide in patients with type 2 diabetes

    WANG Feiyu1， JIANG Zhen2， LIU Yiwei1

    (1. Department of Pharmacy； 2. Department of Endocrinology， the First Affiliated Hospital of Fujian Medical University， Fuzhou 350005， China)

    ABSTRACT Objective： To explore the association between the single nucleotide polymorphisms (SNPs) on a glucagonlike peptide-1 receptor (GLP-1R) gene and the efficacy of liraglutide in patients with type 2 diabetes (T2DM). Methods： The T2DM patients were treated with liraglutide for 12 weeks and glycosylated hemoglobin (HbA1c) levels were determined before and after administration ......